 <h1>Conjugated estrogens / medroxyprogesterone Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of conjugated estrogens/medroxyprogesterone include:</b> depression, headache, nausea, and mastalgia. <b>Other side effects include:</b> dizziness, and peripheral edema.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to conjugated estrogens/medroxyprogesterone: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Estrogen with or without progestin should not be used for the prevention of cardiovascular disease or dementia. Increased risks of stroke and deep vein thrombosis in postmenopausal women (50 to 79 years) using estrogen alone have been reported. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and DVT in postmenopausal women (50 to 79 years) using estrogen combined with progestin have been reported. An increased risk of developing probable dementia in postmenopausal women 65 years or older has also been reported in women receiving estrogen alone or estrogen combined with progestin. Unopposed estrogens increase the risk of endometrial cancer. Adding a progestin will reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Diagnostic measures should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. Risks should be assumed to be similar for other doses, combinations, and dosage forms of estrogens and progestins. Estrogens, with or without progestins, should be prescribed at the lowest effective doses and for the shortest duration possible.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, conjugated estrogens / medroxyprogesterone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking conjugated estrogens / medroxyprogesterone:</p><p>
<i>Less common</i>
</p><ul>
<li>Bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>blood in the urine</li>
<li>blurred vision</li>
<li>chest pain</li>
<li>clear or bloody discharge from the nipple</li>
<li>cough or hoarseness</li>
<li>dimpling of the breast skin</li>
<li>dizziness</li>
<li>fast, irregular, pounding, or racing heartbeat or pulse</li>
<li>feeling faint, dizzy, or lightheaded</li>
<li>feeling of warmth or heat</li>
<li>fever or chills</li>
<li>flushing or redness of the skin, especially on the face and neck</li>
<li>headache</li>
<li>inverted nipple</li>
<li>lower back or side pain</li>
<li>lump in the breast or under the arm</li>
<li>nervousness</li>
<li>pain during sexual intercourse</li>
<li>painful or difficult urination</li>
<li>persistent crusting or scaling of the nipple</li>
<li>pounding in the ears</li>
<li>redness or swelling of the breast</li>
<li>severe cramping of the uterus</li>
<li>sore on the skin of the breast that does not heal</li>
<li>sweating</li>
<li>thick, white vaginal discharge with no odor or with a mild odor</li>
<li>tingling of the hands or feet</li>
<li>unusual weight gain or loss</li>
<li>vaginal bleeding that is unusual and heavy</li>
<li>vaginal or genital itching</li>
<li>vaginal yeast infection</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Absent, missed, or irregular menstrual periods</li>
<li>acid or sour stomach</li>
<li>anxiety</li>
<li>backache</li>
<li>breast pain or tenderness</li>
<li>confusion</li>
<li>constipation</li>
<li>darkened urine</li>
<li>decreased vision or other changes in vision</li>
<li>difficulty with speaking</li>
<li>double vision</li>
<li>fainting</li>
<li>heartburn</li>
<li>inability to move the arms, legs, or facial muscles</li>
<li>inability to speak</li>
<li>indigestion</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>pain or discomfort in the arms, jaw, back, or neck</li>
<li>pain or feeling of pressure in the pelvis</li>
<li>pain, redness, or swelling in the arm or leg</li>
<li>painful or tender cysts in the breasts</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>slow speech</li>
<li>sudden shortness of breath or troubled breathing</li>
<li>unexpected or excess milk flow from the breasts</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of conjugated estrogens / medroxyprogesterone may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>depression</li>
<li>excess gas in the stomach or intestines</li>
<li>lack or loss of strength</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blemishes on the skin</li>
<li>body aches or pain</li>
<li>congestion</li>
<li>depersonalization</li>
<li>diarrhea</li>
<li>difficulty with moving</li>
<li>dry skin</li>
<li>dryness of the vagina</li>
<li>dysphoria</li>
<li>euphoria</li>
<li>excessive muscle tone</li>
<li>feeling paranoid</li>
<li>flu-like symptoms</li>
<li>fullness or swelling of the breasts</li>
<li>hair loss or thinning of the hair</li>
<li>headache, severe and throbbing</li>
<li>leg cramps</li>
<li>loss of bladder control</li>
<li>menstrual periods that are longer or heavier</li>
<li>muscle pain or stiffness</li>
<li>pain in the joints</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>pimples or acne</li>
<li>quick to react or overreact emotionally</li>
<li>rapidly changing moods</li>
<li>rash</li>
<li>sleeplessness</li>
<li>sore mouth or tongue</li>
<li>stuffy or runny nose</li>
<li>tender, swollen glands in the neck</li>
<li>tightness of the chest or wheezing</li>
<li>trouble with sleeping</li>
<li>trouble with swallowing</li>
<li>vaginal discharge that is clear or white</li>
<li>voice changes</li>
<li>white patches in the mouth or on the tongue</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Changes in appetite</li>
<li>hives or welts</li>
<li>inability to have or keep an erection</li>
<li>increased hair growth, especially on the face</li>
<li>increased interest in sexual intercourse</li>
<li>irritability</li>
<li>loss in sexual ability, desire, drive, or performance</li>
<li>loss of scalp hair</li>
<li>pain in the ankles or knees</li>
<li>painful, red lumps under the skin, mostly on the legs</li>
<li>patchy brown or dark brown discoloration of the skin</li>
<li>redness of the skin</li>
<li>weight changes</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to conjugated estrogens / medroxyprogesterone: oral tablet</i></p><h3>General</h3><p>The most commonly reported adverse events have included abdominal pain, asthenia, back pain, headache, flatulence, nausea, depression, pruritus, breast pain, dysmenorrhea, and leukorrhea.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain, generalized edema, hypertension, vasodilation, edema </p>
<p><b>Uncommon</b> (0.1% to 1%): Palpitation</p>
<p><b>Postmarketing reports</b>: Deep and superficial venous thrombosis, pulmonary embolism, superficial thrombophlebitis, myocardial infarction, stroke, increase in blood pressure<sup>[Ref]</sup></p><p>The Women's Health Initiative (WHI) sub-study reports an increased risk of deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction in postmenopausal women 50 to 79 years old with a duration of 5.6 years of daily conjugated estrogen 0.625 mg-medroxyprogesterone 2.5 mg use compared with placebo.  The WHI estrogen-alone study reported increased risks of stroke and DVT during 7.1 years of daily conjugated estrogen treatment.  </p>
<p></p>
<p>-Stroke Risk (WHI substudy; conjugated estrogen 0.625 mg-medroxyprogesterone 2.5 mg daily): A statistically significant increased stroke risk: 33 versus 25 per 10,000 women-years </p>
<p>-Coronary Heart Disease (WHI substudy; conjugated estrogen 0.625 mg-medroxyprogesterone 2.5 mg): A statistically non-significant increased risk: 41 versus 34 per 10,000 women-years</p>
<p>-Venous Thromboembolism (VTE): (WHI substudy; conjugated estrogen 0.625 mg-medroxyprogesterone 2.5 mg): A statistically significant (VTE) risk: 35 versus 17 per 10,000 women-years.  Specifically, DVT: 26 versus 13 per 10,000 women-years and PE:18 versus 8 per 10,000 women-years </p>
<p></p>
<p>The Heart and Estrogen/Progestin Replacement Study (HERS) demonstrated no cardiovascular benefit in postmenopausal women with established coronary heart disease (CHD) taking daily conjugated estrogen 0.625 mg-medroxyprogesterone 2.5 mg (average follow-up of 4.1 years).  In the HERS II study, an open label extension of HERS, an additional 2.7 years of follow-up showed rates of CHD remained comparable to placebo.<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Breast neoplasm </p>
<p><b>Uncommon</b> (0.1% to 1%): Endometrial hyperplasia</p>
<p><b>Postmarketing reports</b>: Ovarian cancer, endometrial hyperplasia, endometrial cancer, breast cancer<sup>[Ref]</sup></p><p>Breast Cancer: An increased risk of breast cancer was reported in the WHI substudy of daily conjugated estrogen 0.626 mg-medroxyprogesterone 2.5 mg use.  After a mean follow-up of 5.6 years, the risk was 41 versus 33 cases per 10,000 women.  In the women taking conjugated estrogen-medroxyprogesterone, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage.  Metastatic disease was rate and not different compared to placebo.  </p>
<p></p>
<p>Ovarian Cancer: A statistically non-significant risk of ovarian cancer was reported in the WHI substudy of daily conjugated estrogen 0.626 mg-medroxyprogesterone 2.5 mg use.  After a mean follow-up of 5.6 years, the risk was 4 versus 3 cases per 10,000 women.  A large meta-analysis showed a significant increased risk of ovarian cancer in women using both estrogen-alone and estrogen plus progestin.  The duration of hormone therapy use associated with an increased risk of ovarian cancer is unknown.<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): Breast pain (up to 36%) </p>
<p><b>Common</b> (1% to 10%): Breast enlargement </p>
<p><b>Uncommon</b> (0.1% to 1%): Breast engorgement </p>
<p><b>Postmarketing reports</b>: Breast tenderness, breast enlargement, breast pain, nipple discharge, galactorrhea, fibrocystic breast changes, changes in libido<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Dysmenorrhea (up to 13%) </p>
<p><b>Common</b> (1% to 10%): Pelvic pain, cervix disorder, leukorrhea, menstrual disorder, metrorrhagia, suspicious PAP smear, vaginal moniliasis, vaginitis, uterine spasm, vaginal hemorrhage</p>
<p><b>Uncommon</b> (0.1% to 1%): Menorrhagia, urinary incontinence, hematuria, urinary tract infection, vaginal dryness</p>
<p><b>Postmarketing reports</b>: Abnormal uterine bleeding, dysmenorrhea or pelvic pain, increase in size of uterine leiomyomata, vaginitis, vaginal candidiasis, amenorrhea, changes in cervical secretion<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Anaphylaxis, angioedema, hypersensitivity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Decreased glucose tolerance (hyperglycemia), weight gain </p>
<p><b>Uncommon</b> (0.1% to 1%): Increased appetite</p>
<p><b>Postmarketing reports</b>: Appetite changes, weight increases and decreases, glucose intolerance, increased triglycerides<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain (up to 17%) </p>
<p><b>Common</b> (1% to 10%): Diarrhea, dyspepsia, eructation, flatulence, nausea</p>
<p><b>Frequency not reported</b>: Gallbladder disease </p>
<p><b>Postmarketing reports</b>: Nausea, vomiting, abdominal pain, bloating, increased incidence of gallbladder disease, pancreatitis ischemic colitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, Rash </p>
<p><b>Uncommon</b> (0.1% to 1%): Acne, alopecia, dry skin, sweating, skin discoloration</p>
<p><b>Postmarketing reports</b>: Chloasma or melasma that may persist when drug is discontinue, erythema multiforme, erythema nodosum, loss of scalp hair, hirsutism, pruritus, urticaria, rash, acne<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, leg cramps </p>
<p><b>Postmarketing reports</b>: Arthralgia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 19%) </p>
<p><b>Common</b> (1% to 10%): Migraine, dizziness, hypertonia</p>
<p><b>Postmarketing reports</b>: Headache, migraine, dizziness, exacerbation of chorea, exacerbation of epilepsy, growth potentiation of benign meningioma<sup>[Ref]</sup></p><p>In the WHIMS (Women's Health Initiative Memory Study) an ancillary study of WHI, the absolute risk of probable dementia for conjugated estrogen 0.625 mg-medroxyprogesterone 2.5 mg was 45 versus 22 cases per 10,000 women-years.  These studies were conducted in women 65 to 79 years old and therefore it is unknown if this risk applies to younger postmenopausal women.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Emotional lability, depression, Insomnia, nervousness, anxiety </p>
<p><b>Postmarketing reports</b>: Mental depression, mood disturbances, anxiety, irritability, dementia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Cholestatic jaundice<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pharyngitis, sinusitis </p>
<p><b>Postmarketing reports</b>: Asthma exacerbation<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia, pain<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Flu syndrome</p>
<p><b>Uncommon</b> (0.1% to 1%): Infection, moniliasis</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA. </p><p id="ref_2">2. "Product Information. Prempro (conjugated estrogens-medroxyprogesterone)." Wyeth-Ayerst Laboratories, Philadelphia, PA. </p><p id="ref_3">3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women." JAMA 280 (1998): 605-13</p><p id="ref_4">4. Fukutomi T, Nanasawa T, Yamamoto H, Adachi I, Watanabe T "The induction of a hypercoagulable state by medroxyprogesterone  acetate in breast cancer patients." Jpn J Surg 20 (1990): 665-70</p><p id="ref_5">5. The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA 273 (1995): 199-208</p><p id="ref_6">6. Schwartz J, Freeman R, Frishman W "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol 35 (1995): 1-16</p><p id="ref_7">7. Wren BG, Routledge DA "Blood pressure changes: oestrogens in climacteric women." Med J Aust 2 (1981): 528-31</p><p id="ref_8">8. Barrett-Connor E, Bush TL "Estrogen and coronary heart disease in women." JAMA 265 (1991): 1861-7</p><p id="ref_9">9. Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS "Noncontraceptive estrogens and myocardial infarction in young women." JAMA 244 (1980): 339-42</p><p id="ref_10">10. "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_11">11. Stampfer MJ, Colditz GA, Willett WC, et al. "Postmenopausal estrogen and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study." N Engl J Med 325 (1991): 756-62</p><p id="ref_12">12. Astedt B, Jeppsson S, Pandolfi M "Fibrinolytic activity of veins during use of depot  medroxyprogesterone acetate as a contraceptive." Fertil Steril 23 (1972): 489-92</p><p id="ref_13">13. Herrington DM "The HERS Trial results: paradigms lost?" Ann Intern Med 131 (1999): 463-6</p><p id="ref_14">14. Grady D, Rubin SM, Petiti DB, et al. "Hormone therapy to prevent disease and prolong life in postmenopausal women." Ann Intern Med 117 (1992): 1016-36</p><p id="ref_15">15. Crane MG, Harris JJ, Winsor W 3d "Hypertension, oral contraceptive agents, and conjugated estrogens." Ann Intern Med 74 (1971): 13-21</p><p id="ref_16">16. Yamamoto H, Noguchi S, Miyauchi K, Inaji H, Imaoka S, Koyama H, Iwanaga T "Changes in hematologic parameters during treatment with  medroxyprogesterone acetate for breast cancer." Jpn J Cancer Res 82 (1991): 420-5</p><p id="ref_17">17. Grodstein F, Stampfer MJ, Manson JE "Postmenopausal estrogen and progestin use and the risk of cardiovascular disease." N Engl J Med 335 (1996): 453-61</p><p id="ref_18">18. Crane MG, Harris JJ "Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system." Am J Med Sci 276 (1978): 33-55</p><p id="ref_19">19. Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972): 97-102</p><p id="ref_20">20. Pripp U, Hall G, Csemiczky G, Eksborg S, Landgren BM, SchenckGustafsson K "A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease." J Hypertens 17 (1999): 1379-86</p><p id="ref_21">21. "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_22">22. Barrett-Connor E, Wingard DL, Criqui MH "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA 261 (1989): 1095-2100</p><p id="ref_23">23. Jick H, Dinan B, Rothman KJ "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA 239 (1978): 1407-8</p><p id="ref_24">24. Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994): 1062-71</p><p id="ref_25">25. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA "Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women." JAMA 274 (1995): 137-42</p><p id="ref_26">26. Gordon J, Reagan JW, Finkle WD, Ziel HK "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med 297 (1977): 570-1</p><p id="ref_27">27. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S "Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study." Am J Epidemiol 134 (1991): 1386-95</p><p id="ref_28">28. Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB "Depot medroxyprogesterone acetate and breast cancer." JAMA 273 (1995): 799-807</p><p id="ref_29">29. Lavecchia C "Depot-medroxyprogesterone acetate, other injectable contraceptives, and cervical neoplasia." Contraception 49 (1994): 223-30</p><p id="ref_30">30. Chilvers C "Breast cancer and depot-medroxyprogesterone acetate - a review." Contraception 49 (1994): 211-22</p><p id="ref_31">31. Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL Jr, Knapp RC, Stolley PD, Schottenfeld D "Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens." N Engl J Med 313 (1985): 969-72</p><p id="ref_32">32. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C "Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study." BMJ 298 (1989): 147-51</p><p id="ref_33">33. Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol 114 (1981): 497-506</p><p id="ref_34">34. "Breast cancer and depot-medroxyprogesterone acetate: a multinational  study. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 338 (1991): 833-8</p><p id="ref_35">35. "Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial  ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid  Contraceptives." Int J Cancer 49 (1991): 191-5</p><p id="ref_36">36. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S "Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study." Am J Epidemiol 134 (1991): 1375-85</p><p id="ref_37">37. Liang AP, Levenson AG, Layde PM, Shelton JD, Hatcher RA, Potts M, Michelson MJ "Risk of breast, uterine corpus, and ovarian cancer in women receiving  medroxyprogesterone injections." JAMA 249 (1983): 2909-12</p><p id="ref_38">38. Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med 300 (1979): 9-13</p><p id="ref_39">39. "Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer.  The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer 49 (1991): 182-5</p><p id="ref_40">40. Thomas DB, Persing JP, Hutchinson WB "Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases." J Natl Cancer Inst 69 (1982): 1017-25</p><p id="ref_41">41. Oberle MW, Rosero-Bixby L, Irwin KL, Fortney JA, Lee NC, Whatley AS, Bonhomme MG "Cervical cancer risk and use of depot-medroxyprogesterone acetate in  Costa Rica." Int J Epidemiol 17 (1988): 718-23</p><p id="ref_42">42. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C "The risk of breast cancer after estrogen and estrogen-progestin replacement." N Engl J Med 321 (1989): 293-7</p><p id="ref_43">43. Colditz GA, Hankinson SE, Hunter DJ, et al. "The use of estrogens and progestins and the risk of breast cancer in postmenopausal women." N Engl J Med 332 (1995): 1589-93</p><p id="ref_44">44. Lumbiganon P "Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary." Contraception 49 (1994): 203-9</p><p id="ref_45">45. "Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial  cancer. The WHO Collaborative Study of Neoplasia and Steroid  Contraceptives." Int J Cancer 49 (1991): 186-90</p><p id="ref_46">46. Jordan A "Toxicology of depot medroxyprogesterone acetate." Contraception 49 (1994): 189-201</p><p id="ref_47">47. "Breast cancer, cervical cancer, and depot medroxyprogesterone  acetate. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 2 (1984): 1207-8</p><p id="ref_48">48. Gray LA Sr, Christopherson WM, Hoover RN "Estrogens and endometrial carcinoma." Obstet Gynecol 49 (1977): 385-9</p><p id="ref_49">49. Buring JE, Bain CJ, Ehrmann RL "Conjugated estrogen use and risk of endometrial cancer." Am J Epidemiol 124 (1986): 434-41</p><p id="ref_50">50. "Depot-medroxyprogesterone acetate (DMPA) and risk of invasive  squamous cell cervical cancer. The WHO Collaborative Study of  Neoplasia and Steroid Contraceptives." Contraception 45 (1992): 299-312</p><p id="ref_51">51. Hoover R, Glass A, Finkle WD, Azevedo D, Milne K "Conjugated estrogens and breast cancer risk in women." J Natl Cancer Inst 67 (1981): 815-20</p><p id="ref_52">52. Woodruff JD, Pickar JH "Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone." Am J Obstet Gynecol 170 (1994): 1213-23</p><p id="ref_53">53. Obrink A, Bunne G, Collen J, Tjernberg B "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand 58 (1979): 123</p><p id="ref_54">54. Molitch ME, Oill P, Odell WD "Massive hyperlipemia during estrogen therapy." JAMA 227 (1974): 522-5</p><p id="ref_55">55. Spellacy WN, Buhi WC, Birk SA "Stimulated plasma prolactin levels in women using medroxyprogesterone  acetate or an intrauterine device for contraception." Fertil Steril 26 (1975): 970-81</p><p id="ref_56">56. Wortsman J, Hirschowitz JS "Galactorrhea and hyperprolactinemia during treatment of polycystic  ovary syndrome." Obstet Gynecol 55 (1980): 460-3</p><p id="ref_57">57. Siminoski K, Goss P, Drucker DJ "The Cushing syndrome induced by medroxyprogesterone acetate." Ann Intern Med 111 (1989): 758-60</p><p id="ref_58">58. Learoyd D, McElduff A "Medroxyprogesterone induced Cushing's syndrome." Aust N Z J Med 20 (1990): 824-5</p><p id="ref_59">59. Grenfell A, Rudenski A, Watts M, Wiltshire C, Day JL, Gray IP "Cushing's syndrome and medroxyprogesterone acetate" Lancet 336 (1990): 256</p><p id="ref_60">60. Donckier JE, Michel LA, Buysschaert M "Cushing syndrome and medroxyprogesterone acetate" Lancet 335 (1990): 1094</p><p id="ref_61">61. Virutamasen P, Leepipatpaiboon S, Kriengsinyot R, Vichaidith P, Muia PN, Sekaddekigondu CB, Mati JKG, Forest MG, Dikkeschei LD "Pharmacodynamic effects of depot-medroxyprogesterone acetate (DMPA) administered to lactating women on their male infants." Contraception 54 (1996): 153-7</p><p id="ref_62">62. Chaudhury RR, Chompootaweep S, Dusitsin N, Friesen H, Tankeyoon M "The release of prolactin by medroxy-progesterone acetate in human  subjects." Br J Pharmacol 59 (1977): 433-4</p><p id="ref_63">63. Mukherjea M, Mukherjee P, Biswas R "Long-term contraception with Depo-Provera: a clinical evaluation." Int J Fertil 25 (1980): 122-6</p><p id="ref_64">64. Fraser IS "Menstrual changes associated with progestogen-only contraception." Acta Obstet Gynecol Scand Suppl 134 (1986): 21-7</p><p id="ref_65">65. Belsey EM "Menstrual bleeding patterns in untreated women and with long-acting  methods of contraception. Task Force on Long-Acting Systemic Agents  for Fertility Regulation." Adv Contracept 7 (1991): 257-70</p><p id="ref_66">66. Fraser IS "A survey of different approaches to management of menstrual  disturbances in women using injectable contraceptives." Contraception 28 (1983): 385-97</p><p id="ref_67">67. Sapire KE "A study of bleeding patterns with two injectable contraceptives given  postpartum and the effect of two non-hormonal treatments." Adv Contracept 7 (1991): 379-87</p><p id="ref_68">68. Kora S, Virkar K "Incidence of pregnancy, changes in menstrual pattern, and recovery of  endometrial function after discontinuation of medroxyprogesterone  acetate therapy." Fertil Steril 26 (1975): 121-5</p><p id="ref_69">69. Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994): 1543-9</p><p id="ref_70">70. Kaunitz AM "Injectable depot medroxyprogesterone acetate contraception: An update for U.S. clinicians." Int J Fertil Womens Med 43 (1998): 73-83</p><p id="ref_71">71. Julian TM "Pseudoincontinence secondary to unopposed estrogen replacement in the surgically castrate premenopausal female." Obstet Gynecol 70 (1987): 382-3</p><p id="ref_72">72. Archer DF, Pickar JH, Bottiglioni F "Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate." Obstet Gynecol 83 (1994): 686-92</p><p id="ref_73">73. Searcy CJ, Kushner M, Nell P, Beckmann CR "Anaphylactic reaction to intravenous conjugated estrogens." Clin Pharm 6 (1987): 74-6</p><p id="ref_74">74. Caucino JA, Armenaka M, Rosenstreich DL "Anaphylaxis associated with a change in premarin dye formulation." Ann Allergy 72 (1994): 33-5</p><p id="ref_75">75. Brooks GG "Anaphylactoid shock with medroxyprogesterone acetate: A case report." J La State Med Soc 126 (1974): 397-9</p><p id="ref_76">76. Zacest R, Cushway A, Haines C, Cox LW "Hypersensitivity reaction to Depo-Provera" Med J Aust 1 (1982): 12</p><p id="ref_77">77. Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993): 207-14</p><p id="ref_78">78. Teichmann AT, Wander HE, Cremer P, et al. "Medroxyprogesterone acetate and lipid metabolic changes." Arzneimittelforschung 37 (1987): 573-77</p><p id="ref_79">79. Harrison RF, Magill P, Kilminster SG "Impact of a new formulation of low-dose micronised medroxyprogesterone and 17-beta estradiol on lipid profiles in menopausal women." Clin Drug Invest 16 (1998): 93-9</p><p id="ref_80">80. Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6</p><p id="ref_81">81. Amatayakul K, Sivasomboon B, Thanangkul O "A study of the mechanism of weight gain in medroxyprogesterone  acetate users." Contraception 22 (1980): 605-22</p><p id="ref_82">82. Barnes RB, Roy S, Lobo RA "Comparison of lipid and androgen levels after conjugated estrogen or  depo-medroxyprogesterone acetate treatment in postmenopausal women." Obstet Gynecol 66 (1985): 216-9</p><p id="ref_83">83. Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989): 619-32</p><p id="ref_84">84. Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986): 587-94</p><p id="ref_85">85. McClennan BL "Ischemic colitis secondary to Premarin: report of a case." Dis Colon Rectum 19 (1976): 618-20</p><p id="ref_86">86. Perusse R, Morency R "Oral pigmentation induced by Premarin." Cutis 48 (1991): 61-4</p><p id="ref_87">87. Boston Collaborative Drug Surveilance Program "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med 290 (1974): 15-9</p><p id="ref_88">88. Husson RN, Mueller BU, Farley M, Woods L, Kovacs A, Goldsmith JC, Ono J, Lewis LL, Balis FM, Brouwers P, Avramis VI, Churc "Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection." Pediatrics 93 (1994): 316-22</p><p id="ref_89">89. Cundy T, Cornish J, Roberts H, Elder H, Reid IR "Spinal bone density in women using depot medroxyprogesterone contraception." Obstet Gynecol 92 (1998): 569-73</p><p id="ref_90">90. The Writing Group for the PEPI Trial "Effects of hormone therapy on bone mineral density." JAMA 276 (1996): 1389-96</p><p id="ref_91">91. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR "Bone density in women receiving depot medroxyprogesterone acetate for  contraception [published erratum appears in BMJ 1991 Jul27;303(6796):220]." BMJ 303 (1991): 13-6</p><p id="ref_92">92. OrrWalker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR "The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women." Clin Endocrinol 49 (1998): 615-8</p><p id="ref_93">93. Gbolade B, Ellis S, Murby B, Randall S, Kirkman R "Bone density in long term users of depot medroxyprogesterone acetate." Br J Obstet Gynaecol 105 (1998): 790-4</p><p id="ref_94">94. Steiger MJ, Quinn NP "Hormone replacement therapy induced chorea." BMJ 302 (1991): 762</p><p id="ref_95">95. Oppenheim G "A case of rapid mood cycling with estrogen: implications for therapy." J Clin Psychiatry 45 (1984): 34-5</p><p id="ref_96">96. Meyer WJ, 3d  Wiener I, Emory LE, Cole CM, Isenberg N, Fagan CJ, Thompson JC "Cholelithiasis associated with medroxyprogesterone acetate therapy in  men." Res Commun Chem Pathol Pharmacol 75 (1992): 69-84</p><p id="ref_97">97. Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977): 357-9</p><p id="ref_98">98. Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988): 115-9</p><p id="ref_99">99. Riippa P, Kauppila A, Sundstrom H, Vihko R "Hepatic impairment during simultaneous administration of  medroxyprogesterone acetate and tamoxifen in the treatment of  endometrial and ovarian carcinoma." Anticancer Res 4 (1984): 109-12</p><p id="ref_100">100. Jick SS, Walker AM, Jick H "Conjugated estrogens and fibrocystic breast disease." Am J Epidemiol 124 (1986): 746-51</p><p id="ref_101">101. Pastides H, Najjar MA, Kelsey JL "Estrogen replacement therapy and fibrocystic breast disease." Am J Prev Med 3 (1987): 282-6</p></div>
<div class="more-resources" id="moreResources">
<h2>More about conjugated estrogens / medroxyprogesterone</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>46 Reviews</li>
<li>Drug class: sex hormone combinations</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Conjugated estrogens and medroxyprogesterone Oral &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Prempro, Premphase</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Atrophic Vaginitis</li>
<li>Atrophic Urethritis</li>
<li>Postmenopausal Symptoms</li>
<li>Oophorectomy</li>
<li>Osteoporosis</li>
<li>Primary Ovarian Failure</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to conjugated estrogens / medroxyprogesterone: oral tablet</i></p><h3>General</h3><p>The most commonly reported adverse events have included abdominal pain, asthenia, back pain, headache, flatulence, nausea, depression, pruritus, breast pain, dysmenorrhea, and leukorrhea.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain, generalized edema, hypertension, vasodilation, edema </p><p><b>Uncommon</b> (0.1% to 1%): Palpitation</p><p><b>Postmarketing reports</b>: Deep and superficial venous thrombosis, pulmonary embolism, superficial thrombophlebitis, myocardial infarction, stroke, increase in blood pressure<sup>[Ref]</sup></p><p>The Women's Health Initiative (WHI) sub-study reports an increased risk of deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction in postmenopausal women 50 to 79 years old with a duration of 5.6 years of daily conjugated estrogen 0.625 mg-medroxyprogesterone 2.5 mg use compared with placebo.  The WHI estrogen-alone study reported increased risks of stroke and DVT during 7.1 years of daily conjugated estrogen treatment.  </p><p></p><p>-Stroke Risk (WHI substudy; conjugated estrogen 0.625 mg-medroxyprogesterone 2.5 mg daily): A statistically significant increased stroke risk: 33 versus 25 per 10,000 women-years </p><p>-Coronary Heart Disease (WHI substudy; conjugated estrogen 0.625 mg-medroxyprogesterone 2.5 mg): A statistically non-significant increased risk: 41 versus 34 per 10,000 women-years</p><p>-Venous Thromboembolism (VTE): (WHI substudy; conjugated estrogen 0.625 mg-medroxyprogesterone 2.5 mg): A statistically significant (VTE) risk: 35 versus 17 per 10,000 women-years.  Specifically, DVT: 26 versus 13 per 10,000 women-years and PE:18 versus 8 per 10,000 women-years </p><p></p><p>The Heart and Estrogen/Progestin Replacement Study (HERS) demonstrated no cardiovascular benefit in postmenopausal women with established coronary heart disease (CHD) taking daily conjugated estrogen 0.625 mg-medroxyprogesterone 2.5 mg (average follow-up of 4.1 years).  In the HERS II study, an open label extension of HERS, an additional 2.7 years of follow-up showed rates of CHD remained comparable to placebo.<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Breast neoplasm </p><p><b>Uncommon</b> (0.1% to 1%): Endometrial hyperplasia</p><p><b>Postmarketing reports</b>: Ovarian cancer, endometrial hyperplasia, endometrial cancer, breast cancer<sup>[Ref]</sup></p><p>Breast Cancer: An increased risk of breast cancer was reported in the WHI substudy of daily conjugated estrogen 0.626 mg-medroxyprogesterone 2.5 mg use.  After a mean follow-up of 5.6 years, the risk was 41 versus 33 cases per 10,000 women.  In the women taking conjugated estrogen-medroxyprogesterone, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage.  Metastatic disease was rate and not different compared to placebo.  </p><p></p><p>Ovarian Cancer: A statistically non-significant risk of ovarian cancer was reported in the WHI substudy of daily conjugated estrogen 0.626 mg-medroxyprogesterone 2.5 mg use.  After a mean follow-up of 5.6 years, the risk was 4 versus 3 cases per 10,000 women.  A large meta-analysis showed a significant increased risk of ovarian cancer in women using both estrogen-alone and estrogen plus progestin.  The duration of hormone therapy use associated with an increased risk of ovarian cancer is unknown.<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): Breast pain (up to 36%) </p><p><b>Common</b> (1% to 10%): Breast enlargement </p><p><b>Uncommon</b> (0.1% to 1%): Breast engorgement </p><p><b>Postmarketing reports</b>: Breast tenderness, breast enlargement, breast pain, nipple discharge, galactorrhea, fibrocystic breast changes, changes in libido<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Dysmenorrhea (up to 13%) </p><p><b>Common</b> (1% to 10%): Pelvic pain, cervix disorder, leukorrhea, menstrual disorder, metrorrhagia, suspicious PAP smear, vaginal moniliasis, vaginitis, uterine spasm, vaginal hemorrhage</p><p><b>Uncommon</b> (0.1% to 1%): Menorrhagia, urinary incontinence, hematuria, urinary tract infection, vaginal dryness</p><p><b>Postmarketing reports</b>: Abnormal uterine bleeding, dysmenorrhea or pelvic pain, increase in size of uterine leiomyomata, vaginitis, vaginal candidiasis, amenorrhea, changes in cervical secretion<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Anaphylaxis, angioedema, hypersensitivity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Decreased glucose tolerance (hyperglycemia), weight gain </p><p><b>Uncommon</b> (0.1% to 1%): Increased appetite</p><p><b>Postmarketing reports</b>: Appetite changes, weight increases and decreases, glucose intolerance, increased triglycerides<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain (up to 17%) </p><p><b>Common</b> (1% to 10%): Diarrhea, dyspepsia, eructation, flatulence, nausea</p><p><b>Frequency not reported</b>: Gallbladder disease </p><p><b>Postmarketing reports</b>: Nausea, vomiting, abdominal pain, bloating, increased incidence of gallbladder disease, pancreatitis ischemic colitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, Rash </p><p><b>Uncommon</b> (0.1% to 1%): Acne, alopecia, dry skin, sweating, skin discoloration</p><p><b>Postmarketing reports</b>: Chloasma or melasma that may persist when drug is discontinue, erythema multiforme, erythema nodosum, loss of scalp hair, hirsutism, pruritus, urticaria, rash, acne<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, leg cramps </p><p><b>Postmarketing reports</b>: Arthralgia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 19%) </p><p><b>Common</b> (1% to 10%): Migraine, dizziness, hypertonia</p><p><b>Postmarketing reports</b>: Headache, migraine, dizziness, exacerbation of chorea, exacerbation of epilepsy, growth potentiation of benign meningioma<sup>[Ref]</sup></p><p>In the WHIMS (Women's Health Initiative Memory Study) an ancillary study of WHI, the absolute risk of probable dementia for conjugated estrogen 0.625 mg-medroxyprogesterone 2.5 mg was 45 versus 22 cases per 10,000 women-years.  These studies were conducted in women 65 to 79 years old and therefore it is unknown if this risk applies to younger postmenopausal women.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Emotional lability, depression, Insomnia, nervousness, anxiety </p><p><b>Postmarketing reports</b>: Mental depression, mood disturbances, anxiety, irritability, dementia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Cholestatic jaundice<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pharyngitis, sinusitis </p><p><b>Postmarketing reports</b>: Asthma exacerbation<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia, pain<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Flu syndrome</p><p><b>Uncommon</b> (0.1% to 1%): Infection, moniliasis</p><p id="ref_1">1. "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA. </p><p id="ref_2">2. "Product Information. Prempro (conjugated estrogens-medroxyprogesterone)." Wyeth-Ayerst Laboratories, Philadelphia, PA. </p><p id="ref_3">3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women." JAMA 280 (1998): 605-13</p><p id="ref_4">4. Fukutomi T, Nanasawa T, Yamamoto H, Adachi I, Watanabe T "The induction of a hypercoagulable state by medroxyprogesterone  acetate in breast cancer patients." Jpn J Surg 20 (1990): 665-70</p><p id="ref_5">5. The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA 273 (1995): 199-208</p><p id="ref_6">6. Schwartz J, Freeman R, Frishman W "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol 35 (1995): 1-16</p><p id="ref_7">7. Wren BG, Routledge DA "Blood pressure changes: oestrogens in climacteric women." Med J Aust 2 (1981): 528-31</p><p id="ref_8">8. Barrett-Connor E, Bush TL "Estrogen and coronary heart disease in women." JAMA 265 (1991): 1861-7</p><p id="ref_9">9. Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS "Noncontraceptive estrogens and myocardial infarction in young women." JAMA 244 (1980): 339-42</p><p id="ref_10">10. "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_11">11. Stampfer MJ, Colditz GA, Willett WC, et al. "Postmenopausal estrogen and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study." N Engl J Med 325 (1991): 756-62</p><p id="ref_12">12. Astedt B, Jeppsson S, Pandolfi M "Fibrinolytic activity of veins during use of depot  medroxyprogesterone acetate as a contraceptive." Fertil Steril 23 (1972): 489-92</p><p id="ref_13">13. Herrington DM "The HERS Trial results: paradigms lost?" Ann Intern Med 131 (1999): 463-6</p><p id="ref_14">14. Grady D, Rubin SM, Petiti DB, et al. "Hormone therapy to prevent disease and prolong life in postmenopausal women." Ann Intern Med 117 (1992): 1016-36</p><p id="ref_15">15. Crane MG, Harris JJ, Winsor W 3d "Hypertension, oral contraceptive agents, and conjugated estrogens." Ann Intern Med 74 (1971): 13-21</p><p id="ref_16">16. Yamamoto H, Noguchi S, Miyauchi K, Inaji H, Imaoka S, Koyama H, Iwanaga T "Changes in hematologic parameters during treatment with  medroxyprogesterone acetate for breast cancer." Jpn J Cancer Res 82 (1991): 420-5</p><p id="ref_17">17. Grodstein F, Stampfer MJ, Manson JE "Postmenopausal estrogen and progestin use and the risk of cardiovascular disease." N Engl J Med 335 (1996): 453-61</p><p id="ref_18">18. Crane MG, Harris JJ "Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system." Am J Med Sci 276 (1978): 33-55</p><p id="ref_19">19. Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972): 97-102</p><p id="ref_20">20. Pripp U, Hall G, Csemiczky G, Eksborg S, Landgren BM, SchenckGustafsson K "A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease." J Hypertens 17 (1999): 1379-86</p><p id="ref_21">21. "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_22">22. Barrett-Connor E, Wingard DL, Criqui MH "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA 261 (1989): 1095-2100</p><p id="ref_23">23. Jick H, Dinan B, Rothman KJ "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA 239 (1978): 1407-8</p><p id="ref_24">24. Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994): 1062-71</p><p id="ref_25">25. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA "Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women." JAMA 274 (1995): 137-42</p><p id="ref_26">26. Gordon J, Reagan JW, Finkle WD, Ziel HK "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med 297 (1977): 570-1</p><p id="ref_27">27. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S "Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study." Am J Epidemiol 134 (1991): 1386-95</p><p id="ref_28">28. Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB "Depot medroxyprogesterone acetate and breast cancer." JAMA 273 (1995): 799-807</p><p id="ref_29">29. Lavecchia C "Depot-medroxyprogesterone acetate, other injectable contraceptives, and cervical neoplasia." Contraception 49 (1994): 223-30</p><p id="ref_30">30. Chilvers C "Breast cancer and depot-medroxyprogesterone acetate - a review." Contraception 49 (1994): 211-22</p><p id="ref_31">31. Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL Jr, Knapp RC, Stolley PD, Schottenfeld D "Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens." N Engl J Med 313 (1985): 969-72</p><p id="ref_32">32. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C "Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study." BMJ 298 (1989): 147-51</p><p id="ref_33">33. Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol 114 (1981): 497-506</p><p id="ref_34">34. "Breast cancer and depot-medroxyprogesterone acetate: a multinational  study. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 338 (1991): 833-8</p><p id="ref_35">35. "Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial  ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid  Contraceptives." Int J Cancer 49 (1991): 191-5</p><p id="ref_36">36. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S "Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study." Am J Epidemiol 134 (1991): 1375-85</p><p id="ref_37">37. Liang AP, Levenson AG, Layde PM, Shelton JD, Hatcher RA, Potts M, Michelson MJ "Risk of breast, uterine corpus, and ovarian cancer in women receiving  medroxyprogesterone injections." JAMA 249 (1983): 2909-12</p><p id="ref_38">38. Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med 300 (1979): 9-13</p><p id="ref_39">39. "Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer.  The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer 49 (1991): 182-5</p><p id="ref_40">40. Thomas DB, Persing JP, Hutchinson WB "Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases." J Natl Cancer Inst 69 (1982): 1017-25</p><p id="ref_41">41. Oberle MW, Rosero-Bixby L, Irwin KL, Fortney JA, Lee NC, Whatley AS, Bonhomme MG "Cervical cancer risk and use of depot-medroxyprogesterone acetate in  Costa Rica." Int J Epidemiol 17 (1988): 718-23</p><p id="ref_42">42. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C "The risk of breast cancer after estrogen and estrogen-progestin replacement." N Engl J Med 321 (1989): 293-7</p><p id="ref_43">43. Colditz GA, Hankinson SE, Hunter DJ, et al. "The use of estrogens and progestins and the risk of breast cancer in postmenopausal women." N Engl J Med 332 (1995): 1589-93</p><p id="ref_44">44. Lumbiganon P "Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary." Contraception 49 (1994): 203-9</p><p id="ref_45">45. "Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial  cancer. The WHO Collaborative Study of Neoplasia and Steroid  Contraceptives." Int J Cancer 49 (1991): 186-90</p><p id="ref_46">46. Jordan A "Toxicology of depot medroxyprogesterone acetate." Contraception 49 (1994): 189-201</p><p id="ref_47">47. "Breast cancer, cervical cancer, and depot medroxyprogesterone  acetate. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 2 (1984): 1207-8</p><p id="ref_48">48. Gray LA Sr, Christopherson WM, Hoover RN "Estrogens and endometrial carcinoma." Obstet Gynecol 49 (1977): 385-9</p><p id="ref_49">49. Buring JE, Bain CJ, Ehrmann RL "Conjugated estrogen use and risk of endometrial cancer." Am J Epidemiol 124 (1986): 434-41</p><p id="ref_50">50. "Depot-medroxyprogesterone acetate (DMPA) and risk of invasive  squamous cell cervical cancer. The WHO Collaborative Study of  Neoplasia and Steroid Contraceptives." Contraception 45 (1992): 299-312</p><p id="ref_51">51. Hoover R, Glass A, Finkle WD, Azevedo D, Milne K "Conjugated estrogens and breast cancer risk in women." J Natl Cancer Inst 67 (1981): 815-20</p><p id="ref_52">52. Woodruff JD, Pickar JH "Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone." Am J Obstet Gynecol 170 (1994): 1213-23</p><p id="ref_53">53. Obrink A, Bunne G, Collen J, Tjernberg B "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand 58 (1979): 123</p><p id="ref_54">54. Molitch ME, Oill P, Odell WD "Massive hyperlipemia during estrogen therapy." JAMA 227 (1974): 522-5</p><p id="ref_55">55. Spellacy WN, Buhi WC, Birk SA "Stimulated plasma prolactin levels in women using medroxyprogesterone  acetate or an intrauterine device for contraception." Fertil Steril 26 (1975): 970-81</p><p id="ref_56">56. Wortsman J, Hirschowitz JS "Galactorrhea and hyperprolactinemia during treatment of polycystic  ovary syndrome." Obstet Gynecol 55 (1980): 460-3</p><p id="ref_57">57. Siminoski K, Goss P, Drucker DJ "The Cushing syndrome induced by medroxyprogesterone acetate." Ann Intern Med 111 (1989): 758-60</p><p id="ref_58">58. Learoyd D, McElduff A "Medroxyprogesterone induced Cushing's syndrome." Aust N Z J Med 20 (1990): 824-5</p><p id="ref_59">59. Grenfell A, Rudenski A, Watts M, Wiltshire C, Day JL, Gray IP "Cushing's syndrome and medroxyprogesterone acetate" Lancet 336 (1990): 256</p><p id="ref_60">60. Donckier JE, Michel LA, Buysschaert M "Cushing syndrome and medroxyprogesterone acetate" Lancet 335 (1990): 1094</p><p id="ref_61">61. Virutamasen P, Leepipatpaiboon S, Kriengsinyot R, Vichaidith P, Muia PN, Sekaddekigondu CB, Mati JKG, Forest MG, Dikkeschei LD "Pharmacodynamic effects of depot-medroxyprogesterone acetate (DMPA) administered to lactating women on their male infants." Contraception 54 (1996): 153-7</p><p id="ref_62">62. Chaudhury RR, Chompootaweep S, Dusitsin N, Friesen H, Tankeyoon M "The release of prolactin by medroxy-progesterone acetate in human  subjects." Br J Pharmacol 59 (1977): 433-4</p><p id="ref_63">63. Mukherjea M, Mukherjee P, Biswas R "Long-term contraception with Depo-Provera: a clinical evaluation." Int J Fertil 25 (1980): 122-6</p><p id="ref_64">64. Fraser IS "Menstrual changes associated with progestogen-only contraception." Acta Obstet Gynecol Scand Suppl 134 (1986): 21-7</p><p id="ref_65">65. Belsey EM "Menstrual bleeding patterns in untreated women and with long-acting  methods of contraception. Task Force on Long-Acting Systemic Agents  for Fertility Regulation." Adv Contracept 7 (1991): 257-70</p><p id="ref_66">66. Fraser IS "A survey of different approaches to management of menstrual  disturbances in women using injectable contraceptives." Contraception 28 (1983): 385-97</p><p id="ref_67">67. Sapire KE "A study of bleeding patterns with two injectable contraceptives given  postpartum and the effect of two non-hormonal treatments." Adv Contracept 7 (1991): 379-87</p><p id="ref_68">68. Kora S, Virkar K "Incidence of pregnancy, changes in menstrual pattern, and recovery of  endometrial function after discontinuation of medroxyprogesterone  acetate therapy." Fertil Steril 26 (1975): 121-5</p><p id="ref_69">69. Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994): 1543-9</p><p id="ref_70">70. Kaunitz AM "Injectable depot medroxyprogesterone acetate contraception: An update for U.S. clinicians." Int J Fertil Womens Med 43 (1998): 73-83</p><p id="ref_71">71. Julian TM "Pseudoincontinence secondary to unopposed estrogen replacement in the surgically castrate premenopausal female." Obstet Gynecol 70 (1987): 382-3</p><p id="ref_72">72. Archer DF, Pickar JH, Bottiglioni F "Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate." Obstet Gynecol 83 (1994): 686-92</p><p id="ref_73">73. Searcy CJ, Kushner M, Nell P, Beckmann CR "Anaphylactic reaction to intravenous conjugated estrogens." Clin Pharm 6 (1987): 74-6</p><p id="ref_74">74. Caucino JA, Armenaka M, Rosenstreich DL "Anaphylaxis associated with a change in premarin dye formulation." Ann Allergy 72 (1994): 33-5</p><p id="ref_75">75. Brooks GG "Anaphylactoid shock with medroxyprogesterone acetate: A case report." J La State Med Soc 126 (1974): 397-9</p><p id="ref_76">76. Zacest R, Cushway A, Haines C, Cox LW "Hypersensitivity reaction to Depo-Provera" Med J Aust 1 (1982): 12</p><p id="ref_77">77. Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993): 207-14</p><p id="ref_78">78. Teichmann AT, Wander HE, Cremer P, et al. "Medroxyprogesterone acetate and lipid metabolic changes." Arzneimittelforschung 37 (1987): 573-77</p><p id="ref_79">79. Harrison RF, Magill P, Kilminster SG "Impact of a new formulation of low-dose micronised medroxyprogesterone and 17-beta estradiol on lipid profiles in menopausal women." Clin Drug Invest 16 (1998): 93-9</p><p id="ref_80">80. Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6</p><p id="ref_81">81. Amatayakul K, Sivasomboon B, Thanangkul O "A study of the mechanism of weight gain in medroxyprogesterone  acetate users." Contraception 22 (1980): 605-22</p><p id="ref_82">82. Barnes RB, Roy S, Lobo RA "Comparison of lipid and androgen levels after conjugated estrogen or  depo-medroxyprogesterone acetate treatment in postmenopausal women." Obstet Gynecol 66 (1985): 216-9</p><p id="ref_83">83. Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989): 619-32</p><p id="ref_84">84. Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986): 587-94</p><p id="ref_85">85. McClennan BL "Ischemic colitis secondary to Premarin: report of a case." Dis Colon Rectum 19 (1976): 618-20</p><p id="ref_86">86. Perusse R, Morency R "Oral pigmentation induced by Premarin." Cutis 48 (1991): 61-4</p><p id="ref_87">87. Boston Collaborative Drug Surveilance Program "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med 290 (1974): 15-9</p><p id="ref_88">88. Husson RN, Mueller BU, Farley M, Woods L, Kovacs A, Goldsmith JC, Ono J, Lewis LL, Balis FM, Brouwers P, Avramis VI, Churc "Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection." Pediatrics 93 (1994): 316-22</p><p id="ref_89">89. Cundy T, Cornish J, Roberts H, Elder H, Reid IR "Spinal bone density in women using depot medroxyprogesterone contraception." Obstet Gynecol 92 (1998): 569-73</p><p id="ref_90">90. The Writing Group for the PEPI Trial "Effects of hormone therapy on bone mineral density." JAMA 276 (1996): 1389-96</p><p id="ref_91">91. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR "Bone density in women receiving depot medroxyprogesterone acetate for  contraception [published erratum appears in BMJ 1991 Jul27;303(6796):220]." BMJ 303 (1991): 13-6</p><p id="ref_92">92. OrrWalker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR "The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women." Clin Endocrinol 49 (1998): 615-8</p><p id="ref_93">93. Gbolade B, Ellis S, Murby B, Randall S, Kirkman R "Bone density in long term users of depot medroxyprogesterone acetate." Br J Obstet Gynaecol 105 (1998): 790-4</p><p id="ref_94">94. Steiger MJ, Quinn NP "Hormone replacement therapy induced chorea." BMJ 302 (1991): 762</p><p id="ref_95">95. Oppenheim G "A case of rapid mood cycling with estrogen: implications for therapy." J Clin Psychiatry 45 (1984): 34-5</p><p id="ref_96">96. Meyer WJ, 3d  Wiener I, Emory LE, Cole CM, Isenberg N, Fagan CJ, Thompson JC "Cholelithiasis associated with medroxyprogesterone acetate therapy in  men." Res Commun Chem Pathol Pharmacol 75 (1992): 69-84</p><p id="ref_97">97. Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977): 357-9</p><p id="ref_98">98. Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988): 115-9</p><p id="ref_99">99. Riippa P, Kauppila A, Sundstrom H, Vihko R "Hepatic impairment during simultaneous administration of  medroxyprogesterone acetate and tamoxifen in the treatment of  endometrial and ovarian carcinoma." Anticancer Res 4 (1984): 109-12</p><p id="ref_100">100. Jick SS, Walker AM, Jick H "Conjugated estrogens and fibrocystic breast disease." Am J Epidemiol 124 (1986): 746-51</p><p id="ref_101">101. Pastides H, Najjar MA, Kelsey JL "Estrogen replacement therapy and fibrocystic breast disease." Am J Prev Med 3 (1987): 282-6</p><h2>More about conjugated estrogens / medroxyprogesterone</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>46 Reviews</li>
<li>Drug class: sex hormone combinations</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Conjugated estrogens and medroxyprogesterone Oral &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Atrophic Vaginitis</li>
<li>Atrophic Urethritis</li>
<li>Postmenopausal Symptoms</li>
<li>Oophorectomy</li>
<li>Osteoporosis</li>
<li>Primary Ovarian Failure</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>